Our portfolio

T cell-directed vaccine and immunotherapy development

Genocea harnesses the power of T-cells to discover life-changing vaccines and immunotherapies. Since T-cell response is critical during the liver stage of disease, Genocea is identifying antigens for future malaria vaccines.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series C
  • Partnered in
    2012
  • Investment lead
    David Rossow
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.